Shanghai/Berlin. Fiagon AG (Fiagon), a company from Hennigsdorf in the German federal state of Brandenburg, is a manufacturer of navigation systems with cutting-edge technology “made in Germany” and is a portfolio company of the ‘High-Tech Gründerfonds’ (HTGF) public-private venture capital investment firm. HTGF has signed a cooperation agreement with one of the most successful Chinese investment banks – Donghai Securities (Donghai). Fiagon is the first project from the Sino-German Strategic Cooperation action plan established at the third Chinese-German governmental meeting held in late October in Beijing.
In Germany, Donghai is supported by the entrepreneur and investor Prof. Dr.-Ing. Kai Desinger who initiated the cooperation between Donghai and HTGF. He helps in the selection process and supports companies such as Fiagon in becoming fit for Donghai and the Chinese market.
The cooperation deal was signed by (image, l. to r.) Prof. Kai Desinger, Zhu Kemin (Donghai) and Dr. Michael Brandkamp (HTGF) at a celebratory signing ceremony chaired by the Chinese Prime Minister Li Keqiang and the German Chancellor Angela Merkel.
New technologies in the field of information and communication technology (ITC) are urgently needed in the rapidly growing Chinese market. The demand for innovations as a means of countering demographic developments, especially in medicine, is greater than ever. The cooperation between Donghai and Fiagon heralds the start of the “Industry 4.0 and Life Science” cooperation.
Aiming at gaining a foothold in the Chinese market, Fiagon has chosen one of China’s most successful investment banks – Donghai – as a strong strategic partner at its side. Fiagon, with its state-of-the-art technology, fits precisely in the focus of Donghai, which concentrates on Life Sciences and Cleantech, Internet of Things (IOT) and Industry 4.0. With Donghai’s commitment, Fiagon strengthens its solid financial basis for continuing its pursuit of a growth-oriented corporate strategy. Donghai mediates capital raising, production establishment, important contacts and opens doors in one of the world’s most important sales markets.
“The cooperation boosts Fiagon’s financial basis for a growth-oriented corporate strategy”, enthuses Prof. Dr.-Ing. Kai Desinger on the successful establishment of strategic support from Donghai and goes on to say: “Donghai also provides its network and strategic expertise, which will be highly beneficial for Fiagon’s market development in the Asian economic region. For Fiagon, this represents another step towards opening up the most important world market.”
Dr. Michael Brandkamp, Managing Director of HTGF adds: “In order to grow, start-ups have to operate internationally. It is very interesting for Fiagon to obtain access to the Chinese markets and to establish production in China. Both are capital-intensive and require support from insiders who know how business is done in China. With Donghai we have an excellent partner here.” “We are delighted to now have Donghai on board, as a highly potent strategic partner in one of our focus markets. Besides the USA, China is the market in which Fiagon is growing fastest”, according to Dr. Timo Krüger, CEO of Fiagon AG.
Donghai was founded in 1993. It is one of the first investment banks to work with a full licence in China. Donghai is a leader with asset management exceeding 30 billion euros in equity investments, as well as in fixed interest, mixed or other innovative banking activities. Through its equity investments and M&A activities, Donghai has built up solid relationships with hundreds of domestic companies, investment banks and other financial institutions. The broad industry coverage is realized with a plentiful flow of resources.
Using its “FlexSensor” technology, Fiagon develops and manufactures innovative next generation surgical navigation systems. Together with world renowned doctors, Fiagon has set a new standard in ENT navigation over recent years with its electromagnetic navigation technology. This unique technology is already used outside China, mainly in Europe and the USA, in oral and maxillofacial surgery, neurosurgery and spinal surgery.